Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients

Loading news article.

Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients | WAPE

Kalaris Therapeutics To Present Phase 1a Data On TH103 Dual‑Targeting VEGF/HSPG Biologic In Neovascular AMD At ASRS 2026; Phase 1b/2 Study Actively Enrolling, Dosing Patients

Article summary

Related companies

Comments —